Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This is a dose escalation trial to evaluate twice daily dosing of the sachet formulation of
BEZ235. This trial will find the maximum tolerated dose (MTD) of the sachet formulation given
twice daily, as well as evaluate pharmacokinetics (PK) and pharmacodynamics (PD) of the twice
daily dosing. Patients will initially be given once daily dosing to determine the PK and PD
of the single daily dose. On Day 9, they will begin twice daily dosing, with half of the
single daily dose divided twice daily, and PK and PD of the twice daily dose will be
determined.